Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Phase 2LP-184Positive

AI Analysis

Summary

Lantern Pharma announced EMA clearance to advance a Phase 1b/2 trial of LP-184 (Zirdafulven) for biomarker-selected advanced bladder cancer, representing progression in the drug's clinical development.

Clinical Trial Data

Phase

1b/2

Outcome Details

EMA-cleared Phase 1b/2 trial advancement in biomarker-selected advanced bladder cancer

Importance:6/10

Sentiment:

0.60

Phase 1b/2bladder cancerEMA clearancebiomarker-selectedZirdafulven

Related Companies

$LTRN

Read the original article

Published by yahoo_finance on July 28, 2026 11:45 AM

Read Original